No Data
Glory Health (02329) announced its interim performance, with a shareholder attributable loss of 58.659 million yuan, a year-on-year narrowing of 78.02%.
Glory Health (02329) announced its interim performance for the six months ending June 30, 2024, with total revenue of 9.87...
GLORY HEALTH: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Glory Health (02329) clarifies: the agreement between the company and Hong Kong Securities Registration Limited Hong Kong Stock Transfer Registry has been terminated on August 19.
Glory Health (02329) issued a clarification, the company and the Hong Kong Share Transfer Registry of the Hong Kong Central Securities Registration Company...
Glory Health Faces Potential Trading Suspension
Glory Health (02329.HK) held a board of directors meeting on August 30 to consider and approve the semi-annual performance.
Glory Health (02329.HK) announced on August 16th that the company will hold a board of directors meeting on August 30th, 2024 (Friday) to consider and approve the unaudited semi-annual performance of the company and its subsidiaries as of June 30th, 2024, and to consider recommending the distribution of dividends (if any).
Glory Health Industry Schedules Financial Review Meeting
No Data
No Data